Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial

The Lancet Neurology

Volumn 15, Issue 2, 2016, Pages 154-165

  Ferreira, Joaquim J ^a   Lees, Andrew ^b   Rocha, José Francisco ^c   Poewe, Werner ^d   Rascol, Olivier ^e   Soares da Silva, Patrício ^c,f,g  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f University of Porto   (Portugal)

^g UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ENTACAPONE; LEVODOPA; OPICAPONE; PLACEBO; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; NITRILE; OXADIAZOLE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BEDTIME DOSAGE; CONSTIPATION; CONTROLLED STUDY; COR PULMONALE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EUROPEAN; FAINTNESS; FEMALE; HEPATITIS; HUMAN; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; OUTCOME ASSESSMENT; PANCREATITIS; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; DYSKINESIA, DRUG-INDUCED; EUROPE; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CATECHOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; EUROPE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; OUTCOME ASSESSMENT (HEALTH CARE); OXADIAZOLES; PARKINSON DISEASE;

EID: 84955282612     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00336-1     Document Type: Article

References (37)

1. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(suppl 3):S2-41.
2. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013, 20:5-15.
3. Aquino CC, Fox SH Clinical spectrum of levodopa-induced complications. Mov Disord 2015, 30:80-89.
4. Capturing and elevating the patient voice Michael J Fox Foundation, (accessed Oct 1, 2015). https://www.michaeljfox.org/foundation/news-detail.php?capturing-and-elevating-the-patient-voice.
5. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005, 20:224-230.
6. Poewe W Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 2009, 72(7 suppl):S65-S73.
7. Olanow CW, Obeso JA, Stocchi F Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677-687.
8. Muller T Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs 2015, 75:157-174.
9. Deane KH, Spieker S, Clarke CE Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004, 4. CD004554.
10. EPAR summary for the public. Tasmar (tolcapone) EMA/388409/2014 European Medicines Agency, (accessed Dec 3, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000132/WC500034729.pdf.
11. Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010, 53:3396-3411.
12. Palma PN, Kiss LE, Soares-Da-Silva P Catechol-O-methyl-transferase inhibitors: present problems and relevance of the new ones. Emerging drugs and targets for Parkinson's disease (RSC drug discovery) 2013, 83-109. Royal Society of Chemistry, London. A. Martinez, C. Gil (Eds.).
13. Palma PN, Bonifacio MJ, Loureiro AI, Soares-da-Silva P Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 2012, 33:970-986.
14. Ferreira JJ, Rocha JF, Falcao A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. Eur J Neurol 2015, 22:815-825.
15. Rocha JF, Falcao A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 2014, 70:1059-1071.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
17. Fahn S, Elton RL Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, 153-164. MacMillan Healthcare Information, Florham, NJ. S. Fahn, C.D. Marsden, M. Goldstein (Eds.).
18. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000, 23:75-81.
19. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002, 73:629-635.
20. Peto V, Jenkinson C, Fitzpatrick R PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998, 245(suppl 1):S10-S14.
21. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22:1901-1911.
22. Guy W Clinical global impressions. ECDEU assessment manual for psychopharmacology 1976, 218-222. Department of Health, Education, and Welfare, Rockville, MD. National Institute of Mental Health (Ed.).
23. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011, 168:1266-1277.
24. Christenson GA, Faber RJ, de Zwaan M, et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994, 55:5-11.
25. ICH topic E 9 statistical principles for clinical trials European Medicines Agency, (accessed Dec 3, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf.
26. Bretz F, Maurer W, Brannath W, Posch M A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009, 28:586-604.
27. Dmitrienko A, Wiens BL, Tamhane AC, Wang X Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med 2007, 26:2465-2478.
28. Ferreira JJ, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008, 31:2-18.
29. Hauser RA, Auinger P Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011, 26:813-818. for the Parkinson Study Group.
30. Hauser RA, Gordon MF, Mizuno Y, et al. minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis 2014, 2014:467131.
31. Guideline on the choice of the non-inferiority margin. London European Medicines Agency, (accessed Dec 3, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf.
32. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
33. Mestre TA, Shah P, Marras C, Tomlinson G, Lang AE Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology 2014, 82:1402-1409.
34. Lidstone SC Great expectations: the placebo effect in Parkinson's disease. Handb Exp Pharmacol 2014, 225:139-147.
35. Martinez-Martin P, Deuschl G Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 2007, 22:757-765.
36. Schrag A, Jahanshahi M, Quinn N What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 69:308-312.
37. Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease European Medicines Agency, (accessed Dec 3, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129601.pdf.